John Replogle, a director at Grove Collaborative, has purchased $50,423 worth of company stock, highlighting notable insider activity within the company. The transaction was reported by Investing Us on May 22, 2025.

Vertex Pharmaceuticals is poised to announce its first-quarter earnings for 2025 after the market closes on Monday, May 5th. Analysts project robust financial results, anticipating earnings of $4.24 per share and revenue of $2.85 billion. The company has also set its fiscal year 2025 guidance at earnings per share.

In a recent research note, Taglich Brothers analyst H. Halpern increased the Q1 2025 earnings per share estimate for Air Industries Group to ($0.04) per share, signaling a potentially brighter outlook for the aerospace manufacturer.